Evaluating the decriminalization of non-prescribed buprenorphine in Rhode Island

评估罗德岛州非处方丁丙诺啡的非刑事化

基本信息

批准号：
10549069
负责人：
JOSIAH D RICH
金额：
$ 25.02万
依托单位：
RHODE ISLAND HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-15 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10549069
关键词：
Accounting Affect Agonist Area Attitude Behavior Belief Benzodiazepines Buprenorphine Cessation of life Communities Companions Consumption Criminal Law Data Disincentive Drug Addiction Drug Controls Effectiveness Enrollment Evaluation Event FDA approved Fentanyl Frequencies Goals Harm Reduction Health Health Benefit Health Services Accessibility Heroin Illicit Drugs Interruption Intervention Interview Joints Justice Knowledge Law Enforcement Laws Measures Medicine Methadone Motivation Municipalities Narcotics National Institute of Drug Abuse New York Opioid Opioid agonist Outcome Overdose Overdose reduction Pattern Perception Personal Autonomy Persons Pharmaceutical Preparations Play Police Policies Population Protocols documentation Public Health Publications Recording of previous events Records Recreation Relapse Reporting Research Research Personnel Research Priority Rhode Island Risk Role Safety Science Self Medication Statutes and Laws Stigmatization Structure Substance Use Disorder System Text Time Time Series Analysis Toxicology Training Uncertain Risk Vermont Withdrawal addiction base buprenorphine treatment coronavirus disease design drug misuse experience hazard illicit opioid improved metropolitan mortality non-opioid analgesic novel opioid epidemic opioid injection opioid overdose opioid use disorder opioid withdrawal overdose risk prescription opioid prevent public health relevance public health research rate of change recidivism reduce symptoms response substance misuse treatment program

Accounting Affect Agonist Area Attitude Behavior Belief Benzodiazepines Buprenorphine Cessation of life Communities Companions Consumption Criminal Law Data Disincentive Drug Addiction Drug Controls Effectiveness Enrollment Evaluation Event FDA approved Fentanyl Frequencies Goals Harm Reduction Health Health Benefit Health Services Accessibility Heroin Illicit Drugs Interruption Intervention Interview Joints Justice Knowledge Law Enforcement Laws Measures Medicine Methadone Motivation Municipalities Narcotics National Institute of Drug Abuse New York Opioid Opioid agonist Outcome Overdose Overdose reduction Pattern Perception Personal Autonomy Persons Pharmaceutical Preparations Play Police Policies Population Protocols documentation Public Health Publications Recording of previous events Records Recreation Relapse Reporting Research Research Personnel Research Priority Rhode Island Risk Role Safety Science Self Medication Statutes and Laws Stigmatization Structure Substance Use Disorder System Text Time Time Series Analysis Toxicology Training Uncertain Risk Vermont Withdrawal addiction base buprenorphine treatment coronavirus disease design drug misuse experience hazard illicit opioid improved metropolitan mortality non-opioid analgesic novel opioid epidemic opioid injection opioid overdose opioid use disorder opioid withdrawal overdose risk prescription opioid prevent public health relevance public health research rate of change recidivism reduce symptoms response substance misuse treatment program

展开

项目摘要

ABSTRACT TEXT In July of 2021, Rhode Island became the second state in the nation to decriminalize the possession of non-prescribed buprenorphine (NPB), the partial agonist opioid medication proven effective at treating opioid use disorder (OUD), following Vermont’s decriminalization of NPB the month prior. As the nation contends with the worst fatal overdose crisis in its history, and New York State considers decriminalizing NPB for 20 million residents, there is a time-sensitive need to understand the effects of this decriminalization on people’s consumption of buprenorphine both as part of formal treatment for OUD, and as self-treatment or a form of harm reduction. To date, however, no such evaluation has been conducted. Decriminalizing NPB is a novel response to the overdose crisis, based on evidence that most NPB consumption is for the purpose of self-treatment by people who do not have access to treatment, or do not perceive themselves as ready to succeed in formal treatment programs. It has also been associated with decreases in accidental overdose, and used as a form of protection from an adulterated illicit drug supply. At the same time, concerns among policymakers and legislators persist that consuming NPB unnecessarily delays participation in more comprehensive formal treatment, that when used in combination with non-opioid depressants it can contribute to overdose, and that it contributes to addiction when consumed recreationally, especially by opioid-naïve people. The goal of this project is to explore the effects of decriminalizing NPB on attitudes and beliefs toward buprenorphine in Rhode Island, and changes in buprenorphine’s association with fatal overdoses. It offers the opportunity to systematically examine how a change in the criminal law regulating a treatment medication affects attitudes and behaviors regarding it, allowing for a rapid and broad application of the findings. Using qualitative and quantitative measures, and closely harmonizing their efforts with researchers conducting a companion evaluation in Vermont, the research team will come to an understanding of 1) the knowledge, beliefs, and behaviors regarding decriminalized NPB of people who use illicit opioids; 2) the effects of decriminalized NPB on Rhode Island law enforcement practices, attitudes and beliefs, and 3) any post-decriminalization changes in buprenorphine’s association with fatal overdoses using data from Rhode Island’s State Unintentional Drug Overdose Reporting System. The results will yield both scientific publications and products for distribution to public administration and community stakeholder audiences. The study will produce an understanding of the effects of decriminalized NPB as New York and other states consider what role NPB decriminalization should play in their public health strategies, and will reveal the most insightful research questions and metrics for measuring the health and harm reduction outcomes of decriminalization in an ensuing R01 study.

抽象文本 2021年7月，罗德岛成为全国第二个国家，将其合法化非处方丁丙诺啡（NPB），部分激动剂阿片类药物被证明有效治疗佛蒙特州在前一个月的NPB非刑事化之后。作为国家与历史上最严重的致命过量危机争夺，纽约州也考虑了对于2000万居民的NPB将NPB合法化，有时间敏感的需要了解这种对人们消费丁丙诺啡的非刑事化都是正式治疗的一部分 Oud，作为自我治疗或减少伤害的形式。但是，迄今为止，没有这样的评估基于证据，非刑事化NPB是对过量危机的新反应大多数NPB消费是为了实现无法获得的人的自我治疗治疗，或者不认为自己准备在正式治疗计划中取得成功。它也有与意外过量的下降有关，并用作一种保护形式掺假非法药物供应。同时，政策制定者和立法者的关注仍然存在消耗NPB不必要的延迟参与更全面的正式治疗，当与非阿片类药物抑制剂结合使用时，它可能有助于过量，并且娱乐性消费时，尤其是没有阿片类药物的人会导致成瘾。目标该项目是探讨将NPB合法化对与会者的影响，并相信罗德岛州的丁丙诺啡，以及丁丙诺啡与致命过量的关系变化。它提供了系统地检查刑法的变更如何进行治疗的机会药物影响的参加活动和行为，从而允许快速而广泛的应用发现。使用定性和定量措施，并与他们的努力紧密协调研究人员在佛蒙特州进行伴侣评估，研究团队将进入理解1）关于关于非刑事化的NPB的知识，信念和行为使用非法阿片类药物； 2）非刑事化NPB对罗德岛执法实践的影响，态度和信念，以及3）丁丙诺啡与使用罗德岛州的州无意药过量报告系统的数据致命过量剂量。结果将产生科学出版物和产品，以分发向公共行政和社区利益相关者的受众。该研究将使人们对纽约和其他州的合法化NPB考虑NPB非刑事化应发挥其公共卫生策略，并将揭示最有见地的研究问题和指标在确保R01研究中，用于测量非刑事化的健康和损害减少结果。